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Dynamic regulation of the cancer stem cell
compartment by Cripto-1 in colorectal cancer
F Francescangeli1,2, P Contavalli1, ML De Angelis1, M Baiocchi1, G Gambara3, A Pagliuca1, A Fiorenzano4, C Prezioso4, A Boe1,
M Todaro5, G Stassi5, NP Castro6, K Watanabe7, DS Salomon6, R De Maria2, G Minchiotti4 and A Zeuner*,1
Stemness was recently depicted as a dynamic condition in normal and tumor cells. We found that the embryonic protein Cripto-1
(CR1) was expressed by normal stem cells at the bottom of colonic crypts and by cancer stem cells (CSCs) in colorectal tumor
tissues. CR1-positive populations isolated from patient-derived tumor spheroids exhibited increased clonogenic capacity and
expression of stem-cell-related genes. CR1 expression in tumor spheroids was variable over time, being subject to a complex
regulation of the intracellular, surface and secreted protein, which was related to changes of the clonogenic capacity at the
population level. CR1 silencing induced CSC growth arrest in vitrowith a concomitant decrease of Src/Akt signaling, while in vivo it
inhibited the growth of CSC-derived tumor xenografts and reduced CSC numbers. Importantly, CR1 silencing in established
xenografts through an inducible expression system decreased CSC growth in both primary and metastatic tumors, indicating an
essential role of CR1 in the regulation the CSC compartment. These results point to CR1 as a novel and dynamically regulated
effector of stem cell functions in colorectal cancer.
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Increasing evidence suggests that stemness is not a static
condition, neither in normal cells nor in cancer.1,2 Sponta-
neous interconversion between states of higher and lower
stemness has been observed both in embryonic stem cells
(ESCs) and in adult tissues.3–6 In cancer, the transition
between stem cells and non-stem cells is critical to the
maintenance of a phenotypic equilibrium in which cell
populations rapidly regulate relative hierarchic proportions in
response to external stimuli.7 Stem cell dynamics have been
particularly studied in the intestinal epithelium, where recent
studies provided impressive insight on the behavior of normal
stem cells.8 By contrast, the comprehension of stem cells
dynamics in colorectal cancer (CRC) is at its beginning,
although cancer stem cells (CSC) plasticity has been
observed as the result of therapeutic and microenvironmental
factors and proposed to influence patient outcome.9 In
particular, the extracellular cues that regulate stem cell
metastability in CRC remain largely unknown. Cripto-1
(CR1), also known as teratocarcinoma-derived growth
factor-1 (TDGF-1), is an extracellular glycosylphosphatidyli-
nositol (GPI)-anchored protein expressed in mouse and
human ESCs, where it regulates stem cell differentiation.10
CR1 is usually low or absent in adult tissues but is reactivated
in pathological conditions. Indeed, CR1 expression is rapidly
induced in skeletal muscle upon acute injury and it is required
in the muscle stem cell (satellite cell) compartment to promote
efficient tissue regeneration.11 CR1 is also overexpressed in
several types of human tumors12 where it has a functional role
in malignant transformation.13 Intriguingly, CR1 was found to
be expressed in human ESCs with the highest self-renewal
potential and was identified as a potential surface marker for
an undifferentiated subpopulation in human embryonic carci-
noma cells.14,15We found that CR1 is expressed by cells at the
bottom of colonic crypts in normal human and mouse colon
and by CSCs in human tumor tissues. In multicellular spheroid
cultures of patient-derived colon cancer cells, CR1 expression
was subject to a complex regulation at the intracellular, surface
and secreted levels, which reflected the amount of self-
renewing cells. Furthermore, CR1 silencing decreased CSC
numbers and tumor growth, pointing to a functional role of this
protein in regulating the size of the CSC compartment.
Results
CR1 is expressed in stem cells compartments in normal
colon and CRC. Colon cancer spheroids derived from
primary human tumors have been previously demonstrated
by our laboratory and others to be enriched in CSCs.16–18
Three CRC specimens (detailed in Supplementary Table S1)
were obtained at the time of surgical resection and
established as multicellular spheroid cultures in serum-free
media. Spheroids were mainly composed by CD133+ cells,
indicating that they are prevalently composed by stem
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cells/transit-amplifying progenitors19 but also contained sev-
eral cells positive for cytokeratin-20 (CK20) representing a
more differentiated fraction. Culture in serum-containing
medium led to cell adherence, loss of the AC133 epitope
and widespread CK20 expression (Figure 1a and
Supplementary Figure 1a). We analyzed the expression
and localization of colon-specific and common stem cell
markers in colon spheroids and spheroid-derived adherent
cells (SDAC) and found that, among others, CR1 was
strongly downregulated in SDAC both at the intracellular
and at the surface level (Figure 1b, Supplementary Figure 1b
and Figure 1c, respectively). Flow cytometry analysis of CR1
expression showed variable levels of CR1+ cells in spheroid
lines derived from different patients (between 8 and 33%,
Figure 1d). To investigate whether CR1 was associated with
known stem cell markers in CRC spheroids, we analyzed its
expression relative to Lgr5, Nanog and Ephrin B2 receptor
(EphB2) and found that CR1+ cells represented a fraction of
the EphB2high or Nanog+ population and partly overlapped
with Lgr5+ cells (Figure 1e). To further investigate CR1
expression and localization in the colon, we analyzed tissue
sections of normal and neoplastic colon and found that CR1+
cells localized at the bottom of colonic crypts in normal
mouse (both neonatal and adult, Figures 1f and g) and
human colon (Figure 1h), whereas CR1 expression was
deregulated in cancer, being widely present in neoplastic
tissues of either mouse and human origin (Figures 1g and h).
The expression of CR1 in the colon stem cell compartment
was confirmed by double staining for CR1 and Lgr5 or
EphB2. Double-positive CR1/Lgr5+ or CR1/EphB2high cells
were observed both in normal colon (in rare cells residing at
the bottom of the crypts) and in colon adenocarcinoma, with a
concentrated presence at the invasive front of the tumor
suggesting a potential role for CR1+ cells in modulating
epithelial–mesenchymal transition and metastatic spread
(Figure 1h). The link between CR1 expression and colorectal
CSCs was further supported by the observation that the
expression of CR1 in CRC patients correlates with high
expression of EphB2 or Lgr5 (Supplementary Figure 1c).
These results confirm previous reports that CR1 is expressed
in the neoplastic colon12 and show for the first time its
presence in the stem cell compartments of normal colon
and CRC.
CR1 positivity in tumor spheroids oscillates in corre-
spondence to increased stemness states. To gain further
insights on the role of CR1 in CSCs, we monitored its
expression in colon tumor spheroids over time and we found
a marked oscillation of CR1 surface levels, which fluctuated
between ~ 1 and 60% with a rough sinusoidal distribution
(Figure 2a and Supplementary Figure 2a). Peaks of CR1
positivity corresponded to an increased clonogenic capacity
of the whole spheroid population (Supplementary Figure
2a), suggesting a potential correlation between CR1
expression and stemness potential. In contrast, the expres-
sion of other CSC markers such as CD133 and Lgr5
remained constant over time (Supplementary Figure 2a).
The fluctuation of CR1 expression was not influenced by
oxygen conditions (Supplementary Figure 2b) and was not
determined at the transcriptional level, as CR1 RNA did not
show significant differences when monitored in parallel to
surface expression (Supplementary Figure 2c). To explore
the correlation between CR1 expression and stem cell
properties, we separated spheroid cells positive and
negative for CR1 expression at different time points and
evaluated their ability to generate colonies in soft agar,
assuming that cells with increased stemness capacity were
those able to form larger colonies. We found a significant
correlation between the generation of large colonies and the
presence of CR1-positive cells (Figure 2b), indicating a
causal correlation between CR1 positivity and clonogenic
capacity. Then, we separated CR1-positive and CR1-
negative spheroid populations to monitor their behavior in
liquid culture and to assess the presence of stem cell-
related features. Remarkably, purified CR1+ and CR1−
populations showed rapid modifications of surface CR1
levels, with CR1+ cells undergoing an abrupt loss of CR1
expression (from 90 to 10% after 7 days) whereas CR1−
cells acquired relatively high levels of CR1 expression
(approximately from 0 to 40%; Figure 2c). After sorting, CR1
expression shortly recovered its tendency to oscillate, but
with different phases in the two sorted populations. Finally,
we assessed whether CR1-positive cells displayed
enhanced stem cell features by analyzing Nanog and Lgr5
mRNA levels and β-catenin localization in sorted cells. We
found that CR1-positive cells had increased levels of Nanog
and Lgr5 and a significantly higher nuclear positivity of
β-catenin (Figures 2d and e), suggesting an enrichment of
CSCs. Altogether, these observations suggest that CR1
levels are regulated in CSCs/progenitors both in basal
conditions (in undisturbed spheroid cultures) and upon
perturbation (after sorting), possibly reflecting fluctuations
of the stem/progenitor cell compartment in response to
intrinsic and extrinsic cues.
Synchronized clonal fluctuations are responsible for CR1
oscillation in CSC-enriched cultures. To examine more in
depth the dynamics of CR1 oscillation, we first monitored
surface CR1 expression in three patient-derived spheroid
lines, which all showed a rough sinusoidal trend although with
different phases (Figure 3a). Then, we ought to understand
whether the levels of CR1 were regulated at the clonal level
and whether different clones in spheroid cultures displayed
independent levels of CR1. To do this, we transduced cells
derived from one spheroid line with vectors encoding for six
different fluorescent proteins to allow multicolor clonal cell
marking.20 Transduced cells were sorted and cloned, and
single clones were subsequently assessed for the respective
expression of fluorescent proteins, which displayed a
remarkable stability over time as previously reported
(Figure 3b). Colored clonal cell populations were then pooled
(two pools of three clones each) and CR1 expression was
monitored over time for each clone. We found that clones
belonging to the same pooled population showed a similar
trend of CR1 surface levels (Figure 3c), suggesting that the
dynamics of CR1 expression are dictated by population
forces rather than by independent clonal features.
Fluctuations of CR1 expression reflect a complex
spatiotemporal distribution of the CR1 protein. To gain
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further insights into the process of CR1 fluctuation, we
analyzed the presence of CR1 in different cellular compart-
ments (cytoplasm, total cell membranes and plasmamem-
brane) and in the extracellular milieu, where it can be
released to exert a paracrine activity on surrounding
cells.21,22 To do this, we collected lysates of subcellular
fractions from cultured spheroid cells once a week for
5 weeks. We verified the purity of cellular fractions by
immunoblotting against compartimentalized proteins and
detected the presence of CR1 in the cytosolic and total
membrane fractions, as expected (Supplementary Figure 3).
In parallel, we monitored CR1 surface expression by flow
cytometry and we assessed the levels of CR1 released in the
extracellular medium by ELISA. Interestingly, we found that
CR1 levels were subject to fluctuations not only on the cell
surface but also in the cytoplasmic and total membrane
compartments and in the extracellular medium (Figure 4).
Higher levels of the unmodified form of CR1 in the cytoplasm
corresponded to increased CR1 release and to a lower
surface expression, while the modified (i.e., glycosylated and
fucosylated23) protein was increased in correspondence to
low extracellular levels and high-surface expression. These
observations indicate that CR1 protein is subject to multiple
levels of regulation, not only by posttranslational modifica-
tions but also by intracellular compartimentalization and
extracellular release.
CR1 and the downstream activation of the Glypican–Src–
Akt pathway are essential for CSC growth. To investigate
the functional role of CR1 in colorectal stem-progenitor cells,
we treated spheroid cell lines with small interfering RNAs
(siRNAs) to induce a transient decrease in CR1 expression.
CR1 siRNA were effective in reducing CR1 RNA levels and
resulted in a significant inhibition of colony size in semisolid
culture (Figures 5a and b). Then, we carried out stable CR1
silencing by using lentiviral vectors containing two different
shRNA sequences (detailed in Supplementary Table 2). The
two sequences were both able to induce a strong reduction in
CR1 RNA levels, although at a different extent, in spheroids
(Pt1) as well as in NTERA2 teratocarcinoma cells (Figure 5c).
Functionally, the two shRNAs induced, respectively, a
complete abrogation or a strong reduction of colony formation
in soft agar (Figure 5d) and an equivalent growth inhibitory
effect in liquid culture (Figure 5e). Cell cycle analysis of CSC
stably expressing CR1 shRNA4890 4 days after transduction
showed an accumulation of cells in the G2/M phase of the
cycle (from 11.6 to 26.2%) and a corresponding decrease of
cells in G1 (from 66.5 to 45.4%; Figure 5f). The number of
hypodiploid cells did not change in CR1-silenced CSC, but
we observed a small increase in the percentage of debris/
sub-hypodiploid cells generally indicative of cell death (Debri/
Apo from 2.2 to 6.6%; Figure 5f, right panels). CR1 has been
demonstrated to signal through a Nodal-dependent and a
Nodal-independent pathway,24 the latter being activated by
CR1 binding to Glypican-1 and downstream activation of
c-Src and Akt signaling. To gain insights into the pathway
active downstream of CR1 in colon CSCs, we assessed the
expression of ALK4, Nodal, Glypican-1 and the co-receptor
GRP78 in spheroid cells and found that such factors were all
expressed at the RNA and protein level (Supplementary
Figure 4). Then, we evaluated the effect of CR1 silencing on
the levels of CR1 signaling partners and of selected proteins
involved in cell cycle and apoptosis regulation. Levels of CR1,
phospho-Smad2, Glypican-1, phospho-Src and phospho-Akt
sensibly decreased in silenced cells, whereas levels of Alk4
slightly increased. In CR1-silenced cells we also observed an
increase in polo-like kinase 1 and cyclin D1, confirming the
accumulation of cells in the G2/M phase of the cell cycle. In
addition, we observed a small amount of cleaved PARP in
silenced cells, indicating the occurrence of low levels of cell
death (Figure 5g). These results suggest that CR1 is linked to
the activation of the Glypican–Src–Akt pathway in colorectal
CSCs/progenitors, although we cannot rule out that Nodal-
dependent signaling may have a role in other cellular systems
and in patient tumors.
CR1 downregulation inhibits tumor progression and
decreases CSC content in vivo. To investigate the effects
of CR1 silencing in vivo, we employed a Tet-inducible
lentiviral silencing system that allowed us to achieve CR1
silencing at different stages of tumor formation and progres-
sion. The sh4890 CR1 silencing sequence was cloned into
the TRIPZ Tet-inducible lentiviral vector, which achieved
~75% reduction of CR1 RNA levels as compared with
controls (Figure 6a). CR1 downregulation inhibited spheroid
proliferation and strongly reduced colony formation in
semisolid culture (Figures 6b and c). Cells were then injected
subcutaneously in three groups of immunecompromised
(NOD/SCID ɣ-chain deficient, NSG) mice in order to compare
the growth of tumors generated from control cells (transduced
with the silencing construct but not induced with doxycycline,
thereafter referred to as non-induced), from cells in which
CR1 expression was silenced either at the time of injection
(shCR1 induced from day 0) or at the appearance of palpable
tumors (shCR1 induced from day 21). Tumor xenografts were
then monitored for 1 month. Tumors generated by cells with
CR1 silenced from day 0 grew at a significantly reduced
growth rate (Figure 6d). Notably, also tumors in which CR1
expression was silenced at day 21 also had a significantly,
although less pronounced, reduced growth rate compared
Figure 1 Cripto-1 is expressed in normal and neoplastic colon stem cells. (a) Immunofluorescence staining for CD133 and cytokeratin-20 (CK20) on colon cancer spheroids
(stem) and sphere-derived adherent cells (SDAC). Line Pt1, 60 × magnification, 1,4 × zoom (b) Immunofluorescence detection of stem cell antigens on permeabilized spheroids
(Stem) and SDAC, line Pt2. 60 × magnification, 2x zoom (c) Immunofluorescence detection of CR1 on non-permeabilized spheroids (Stem) and sphere-derived adherent cells
(SDAC), line Pt2. 60 × magnification (d) Flow cytometry analysis of CR1 expression on spheroid lines derived from different patients (detailed in Supplementary Table 1) (e) Flow
cytometry staining of CR1 and either Nanog, Ephrin B2 receptor (EphB2) or Lgr5 on spheroid line Pt1. Numbers refer to the percentage of double-positive cells (f) Whole-mount
in situ hybridization of CR1 on mouse neonatal colon. Magnification 20 × , inset 40 × (g) Anti-CR1 immunohistochemistry on adult mouse normal colon (left panel) and high-grade
adenoma (right panel). Arrows indicate cells with membrane CR1 staining (h) Immunofluorescence staining of CR1/Lgr5 (left) and CR1/EphB2 (right) expression on FFPE
sections of normal colon and colon cancer. Images of colon cancer were taken both from central areas (Colon cancer) and from the invasive edge of the tumor (Invasion front).
Magnification 40 × , detail (yellow square) 3 × zoom
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with controls (Figure 6d). Importantly, an ex vivo analysis of
the clonogenic capacity of cells extracted from the xenografts
showed that CR1 silencing strongly reduced the number of
colony-forming cells (Figure 6e). Moreover, when we ana-
lyzed the effect of CR1 silencing with serial transplantation/
limiting dilution assays, we found that CR1-silenced cells
gave rise to secondary tumors with increased latency,
reduced volume and decreased frequency as compared with
controls, indicating that CR1 downregulation affects the
number of tumor-initiating cells (TICs) in vivo (Figure 6f).
Stem cell quantification of results shown in Figure 6f with the
Extreme Limiting Dilution Analysis (ELDA) method25 indi-
cated an estimated proportion of 1/18 TICs in the Vector
group and 1/69 TICs in the CR1-silenced group (*Po0.05).
Altogether, these results suggest that CR1 has a role in both
tumor initiation and progression through regulation of the
CSC compartment.
CR1 is essential for CSC growth at metastatic sites. A
subpopulation of colon CSC, which has been recently
shown to be characterized by CD44v6 expression, pos-
sesses increased migratory and metastatic properties.26
Double staining of CSC spheroids for CR1 and CD44v6
showed that the majority of CR1+ cells expressed
also CD44v6 (11.4% CR1+CD44v6+ versus 3.9% CR1+
CD44v6−; Figure 7a). In line with a potential role of CR1 in
the regulation of CSC migratory abilities, spheroid cells with
silenced CR1 expression showed a significantly reduced
migration in transwell assays (Figure 7b). To verify whether
CR1 silencing would also affect metastatic growth in vivo,
colon spheroids were double transduced with the inducible
CR1-silencing vector and with a luciferase reporter vector to
allow for tumor bioimaging. Transduced spheroid cells were
then treated with doxycycline to induce CR1 silencing and
injected in the tail vein of NSG mice, which received
doxycycline in the drinking water to maintain CR1 silencing
throughout the experiment. Four months after injection, non-
induced control cells gave rise to lung metastases in all
injected mice, whereas CR1-silenced cells produced very
few metastases (Figure 7c), indicating an essential role of
CR1 for CSC growth at metastatic sites. To provide
additional support to a role of CR1 in metastatic CSC
growth, we injected double-transduced spheroid cells in the
spleen of NSG mice and we waited ~ 1 month to allow tumor
formation (Figure 7d). Tumor-bearing mice were then
splenectomized and divided into two groups, which were,
respectively, left non-induced or administered doxycycline to
activate CR1 silencing (Figure 7d). Mice were regularly
monitored through bioimaging for the appearance and
growth of liver metastasis. Control (non-induced) mice
had a significantly increased rate of metastasis growth
as compared with mice in which CR1 was silenced
(Figure 7e), further supporting a role for CR1 in the growth
of metastatic CSCs.
Discussion
In line with the emerging concept of stem cell plasticity in normal
and neoplastic tissues, we identified the ESC marker CR1 as a
protein dynamically expressed on CRC cells. The dynamic
behavior of CR1 was apparent in multicellular spheroids of
patient-derived cells (composed by a large majority of CD133+
stem/progenitor cells) both in basal culture conditions and upon
separation of CR1-positive and -negative cell populations, which
rapidly changed CR1 surface expression. CR1 expressed on
themembrane of colorectal stem/progenitor cellswas not simply
unstable but followed a roughly sinusoidal trend, reminescent of
fluctuations in stemness regulators that have been shown to
occur in ESCs and to have a key role in the maintenance of
pluripotency.3,27–30 The parallel between the fluctuations of CR1
and that of stemness factors is reinforced by the observation that
cells with the highest expression of CR1 have an increased
clonogenic potential, indicating their enrichment in self-renewing
elements. Notably, the fluctuation of cellular factors is generally
attributed to oscillations of gene expression. By contrast,
fluctuations of CR1 occurred upon small variations in transcript
levels but in the presence of consistent changes in the
subcellular and extracellular distribution of the protein. In this
regard, we show for the first time that CR1 is released by CSCs/
progenitor cells, possibly representing a mechanism that
contributes to a cross-talk between tumor cells. In line with this
hypothesis, stemness has been recently described as a
statistical property of cell populations (rather than a property of
individual cells) that depends both from cell-intrinsic mechan-
isms and from cell-to-cell signals that act as system-level
feedback mechanisms.31,32 Identifying the molecular cues of
intercellular coordination will be essential to interfere with the
adaptive responses of cancer cells to external challenges and
ultimately to achieve long lasting therapeutic effects.
We showed that the cyclic fluctuation of surface CR1
reflects the synchronized expression pattern of different cell
clones present in the same culture. This observation suggests
the existence of feedback mechanisms that coordinate CR1
expression of clones coexisting in the same cell population.
This phenomenon would result in the waves of high CR1
expression in the whole cancer cell population, corresponding
to the waves of high clonogenic potential. Furthermore, this
observation suggests the existence of a coordinated behavior
in the cancer cell population, similar to the mechanisms of
quorum sensing that have been previously postulated on the
basis of mathematical models33 and experimentally observed
in human cell lines.34
Figure 2 Cripto-1 expression is dynamically regulated on the surface of CSC/progenitor cells and is associated with stemness-related features. (a) Flow cytometry analysis of
surface CR1 (indicated as the percentage of positive cells) in the colorectal spheroid line Pt1 at the indicated times of culture. Values are the mean±S.D. of technical triplicates
(b) Self-renewal capacity of sorted Cripto-positive (CR1+) and Cripto-negative (CR1−) cells from spheroid line Pt1 at the indicated times of culture, evaluated as colony formation
in semisolid culture and expressed in bottom panels as normalized colony size/percentage over plated cells. Top panel is a representative illustration of the percentage of large
colonies only. *Po0.05; **Po0.01, ***Po0.001 (c) FACS-based separation of CR1+ and CR1− subpopulations of spheroid line Pt1 (left panel), CR1 surface expression
immediately after sorting (central panels) and monitored for 5 weeks after sorting (right graph). Values are the mean± S.D. of technical triplicates (d) mRNA expression of CR1,
Lgr5 and Nanog on sorted CR1+ and CR1− populations. *Po0.05 (e) Subcellular localization of β-catenin on sorted CR1+ and CR1− populations or mock-sorted (Bulk) cells from
line Pt1 (left) and relative quantification of nuclear versus cytoplasmic β-catenin in the three samples (right). 60 × magnification, 3, 5 × zoom. *Po0.05; **Po0.01
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In normal human and mouse colon, CR1 was expressed by
cells located at the bottom of the crypts possibly representing a
marker of normal colorectal stem cells. However, the role of
CR1 in normal colon is still unknown, as CR1 knockout
embryos die at an early stage due to gross defects in embryonic
symmetry.35 The expression of CR1 was deregulated in CRC,
as previously reported,36 being present on cancer cells
particularly at the invasive front of the tumor. Despite its diffuse
expression on cancer cells, our results show that the highest
levels of CR1 expression are present in Lgr5+ cells and
EphB2high cells, indicating that CR1 may have a specific role in
CSC regulation. The supposed role of CR1 in CSCs seems
corroborated by the observation that CR1 silencing profoundly
affects signaling pathways essential for CSC growth.
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Figure 3 Cripto-1 fluctuation derives from the synchronized oscillation of CR1 expression in different cell clones. (a) Flow cytometry analysis of surface CR1 (indicated as the
percentage of positive cells) at the indicated times of culture in three colorectal spheroid lines derived from different colorectal cancer patients (Pt1–Pt3) (b) Spheroid cells from
line Pt1 were transduced with vectors coding for six different fluorescent reporters, sorted on the basis of fluorescent protein expression (upper panels), single-cell cloned and
retested for reporter expression (lower panels) (c) Cell clones were pooled (two pools of three clones each) and monitored for 5 weeks for CR1 expression, indicated as the
percentage of positive cells. Bottom panels: representative pictures of the pooled clones
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Specifically, CR1 silencing results in a strong decrease of pAkt,
which has been recently indicated as a key factor in colorectal
CSC survival specifically expressed by the tumorigenic/
metastatic fraction.26 Accordingly, our results show that a
reduction of CR1 expression in tumor xenografts inhibits tumor
growth and induces a decrease of CSCnumbers.Moreover, we
observed that CR1 silencing inhibited the growth of metastatic
CSCs in mouse lungs and liver, suggesting that CR1 may be
important for CSC expansion at metastatic sites. These
findings may explain the correlation between elevated CR1
levels and the presence of metachronous metastases found in
colon cancer patients,37 also corroborating the hypothesis that
the state of the CSC compartment may be related to patient
prognosis.38 Altogether, these results indicate CR1 as a new
functional player of CRC stem/progenitor cell regulation and
highlight the dynamic behavior of these cells, which should be
taken into account in order to devise effective anticancer
strategies.
Materials and Methods
Cells and tissues. Colon cancer specimens were obtained from patients
undergoing surgical resection upon informed consent and approval by the Istituto
Superiore di Sanità (ISS) Ethical Committee. Spheroid cultures were established in
serum-free medium containing 20 ng/ml EGF and 10 ng/ml bFGF (PeproTech, Rocky
Hill, NJ, USA) and subsequently kept on ultra-low attachment dishes (Nunc,
Sigma-Aldrich, St. Louis, MO, USA) in a 5% CO2 humidified incubator at 37 °C as
described.39 Spheroids were routinely tested for their ability to produce colon
adenocarcinomas histologically identical to the human tumors of origin when injected
into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory, Ann Arbor,
MI, USA). SDAC were obtained by culturing spheroid cells in 10% serum-containing
DMEM (Gibco-Invitrogen, Carlsbad, CA, USA) for 10 days. Mouse colon samples were
obtained either from healthy neonatal or adult animals or mice with sporadic high-grade
adenoma (Apcflox; LSL-KrasG12D). Human colon samples were obtained from
formalin-fixed paraffin-embedded (FFPE) surgical specimens of neoplastic and
peritumoral (referred to as normal) tissue.
Antibodies and reagents. Polyclonal antibodies against CR1 used for
immunofluorescence and flow cytometry analyses were produced by immunizing
rabbits with purified recombinant soluble CR1 produced in 293 cells.40 Monoclonal
antibodies against Lgr5 (both conjugated and unconjugated) and CD133 (AC133
epitope) were obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Antibodies against CD44v6, Nanog, Musashi, Sox2 and EphB2 (the latter both
Alexa Fluor 488-conjugated and unconjugated) were obtained from R&D System Inc.
(Minneapolis, MN, USA). Anti-CK20 was from Dako (Carpinteria, CA, USA). Alexa
Fluor-conjugated secondary antibodies were obtained from Invitrogen Molecular
Probes. Anti-Alk4, cyclin D1, Glypican-1 and TIM23 were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-β-actin, GAPDH and PARP
were from Sigma-Aldrich. Total Src, p-Src, p-AKT, total AKT, p-smad2, smad2, CD44,
polo-like kinase 1, Bmi1 and β-catenin were from Cell Signaling Technology (Danvers, MA,
USA). Secondary anti-mouse and anti-rabbit antibodies coupled to horseradish peroxidase
were from GE Healthcare (Uppsala, Sweden).
Cell proliferation and self renewal assays. Cell proliferation was
analyzed with the Cell Titer GLO assay (Promega, Madison, WI, USA) as
described39 with a DTX880 plate reader (Beckman Coulter, Brea, CA, USA). For
clonogenic assays, dissociated spheroids were plated in triplicate at 500 cells/well
suspended in 0.3% agarose over a layer of 0.4% agarose. Plates were incubated in
a 5% CO2 humidified incubator at 37 °C and colony counts were performed
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20–25 days after plating. Colonies were stained with crystal violet (0.1% in 10%
MetOH) and classified as follows: micro o30 μm, small 30–60 μm, medium
60–90 μm and large 490 μm. Data represent the percentage of colony numbers
relative to plated cells.
Constructs. For transient CR1 silencing, 1.25 × 105 spheroid cells were plated on
6-well plates in antibiotic-free culture medium and incubated for 4 h at 37 °C in the
presence of 320 nM ON-TARGET PLUS TDGF-1 siRNA (Dharmacon, Lafayette, CO,
USA; L-004832–00–0005) or control siRNA (Non-targeting siRNA D-001810-01), both
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from Thermo Scientific/Life Technologies (Carlsbad, CA, USA). For stable CR1 silencing,
the lentiviral pLKO.1 silencing vectors containing either a non-targeting sequence, the
sh4889 or sh4890 sequences that target the 3′-UTR and the coding sequence of
CR1, respectively, were purchased from Sigma-Aldrich. The sh4890 sequence
was subsequently cloned in the TRIPZ lentiviral inducible vector (Thermo Scientific/
Life Technologies). The lentiviral reporter vector TWEEN-Luc-GFP was constructed by
using pRRL-CMV-PGK-GFP-WPRE (pTWEEN) as a backbone for subcloning a firefly
luciferase NheI/XbaI cDNA fragment extracted from pGL3 (Promega) into the XbaI site at
the 3′ of the CMV promoter.
Clonal marking. Six different lentiviral vectors were used to transduce spheroid
cells: LeGO-C2 (mCherry), LeGO-V2 (Venus), LeGO-Cer2 (Cerulean), TWEEN-GFP
(green), TWEEN-RedFP (red) and pLOX-CFP (Cyan). Cells were separated on the
basis of fluorescent protein expression and single clones were derived from each
fluorescent cell culture by single-cell automated sorting on a 96-well plate. After
1 month, three single-cell-derived spheres for each color were expanded, tested for
fluorescent protein expression and one clone of each color was used for subsequent
experiments.
Whole-mount in situ hybridization. A DNA template was generated from
mouse cDNAs encoding CR1 (entire open reading frame). Antisense RNA probes
were synthesized from 1 μg of linearized cDNA and labeled with either digoxigenin-
UTP (Roche Diagnostics Corporation, Indianapolis, IN, USA) using T3, T7 and SP6
RNA polymerases (Promega). The transcription reaction was carried out at 37 °C for
2 h, followed by DNaseI treatment (Promega). After the quality of the labeled RNA
was assessed by gel electrophoresis, transcripts were ethanol precipitated in 7.5 M
LiCl and TE of pH 8.0 and stored overnight at − 80 °C. Probes were resuspended in
hybridization solution and stored at − 80 °C. Mouse intestines were dissected,
washed in PBS and fixed in 4% paraformaldehyde (PFA) in PBS at 4 °C. In situ
hybridization was performed on 5 μm paraffin-embedded sections. After rehydration in
PBS containing 0.1% Tween20 (PBT), sections were treated with proteinase K
(10 mg/ml) for 3–20 min, and then postfixed in 4% PFA plus 0.2% glutaraldehyde.
Proteinase K was inactivated with 0.2% glycine in PBT. All samples were incubated in
hybridization buffer containing 50% formamide for 2 h at 70 °C and then hybridized at
the same temperature with 0.5 μg/ml labeled RNA probe overnight. Posthybridization
washes and RNase A treatment (100 μg/ml) were subsequently performed. Tissues
were rinsed 3 × 5 minutes in maleic acid buffer (MAB; 0.1 M maleic acid of pH 7.5,
0.15 M NaCl, 0.1% Tween20 and 0.002 M levamisole) and then incubated in blocking
buffer (MAB 10% sheep serum, and 2% blocking reagent, Roche Diagnostics
Corporation), at room temperature for 3 h. Hybridized probes were incubated with
preabsorbed anti–digoxigenin-AP antibody (Roche Diagnostics Corporation) diluted
1 : 4000 in blocking buffer (Roche Diagnostics Corporation) overnight at 4 °C. Tissues
were washed several times with MAB at room temperature, and then developed with
BM purple (Roche Diagnostics Corporation) color substrate for 5–16 h. Reactions
were then stopped with 3 × 5 minutes PBTwashes, and samples postfixed in 4% PFA
plus 0.2% glutaraldehyde.
Immunofluorescence. Colon cancer spheroids were cytospun at low speed
on polylysine-coated glass slides, whereas SDAC were grown on matrigel-coated
coverslips. Typically, cells were fixed in 2% PFA and permeabilized in 0.1% Triton
X-100 (Bio-Rad Laboratories, Hercules, CA, USA) then incubated overnight at 4 °C
with primary antibodies (described in the Antibodies and Reagents section)
dissolved in PBS containing 3% BSA, 0,1% Triton X-100. After two washes in PBS,
cells were incubated with Alexa Fluor-conjugated secondary antibodies for 30 min at
room temperature in the dark, stained for 15 min with DAPI (Invitrogen) diluited in
PBS 3% BSA and subsequently mounted with Prolong-Gold antifade (Invitrogen).
Immunofluorescence staining of FFPE normal and neoplastic human colon tissue
sections was performed as follows: sections were deparaffinized, washed in PBS
and incubated with anti-CR1 antibody40 (1 : 50 in PBS) overnight at 4 °C. After
washing in PBS, sections were incubated with a FITC-conjugated secondary
antibody (1 : 200 in PBS) 1 h at 37 °C and then treated with 4% PFA for 30 min at
room temperature. After an additional washing in PBS, sections were permeabilized
with a brief incubation in a microwave oven with Epitope Retrieval pH-6
(Novocastra-Leica Biosystems, Richmond, IL, USA) followed by 10 min incubation
with cold 0.1% Triton X-100. After washing in PBS, sections were incubated
overnight at 4 °C with anti-EphB2 (1 : 100 in PBS/3% BSA/0.05 Tween20) or anti-
Lgr5 (1 : 100 in PBS/3% BSA/0.05 Tween20) antibodies. After incubation with
rhodamine-conjugated secondary antibodies, nuclei were stained with TOTO-3
(Invitrogen Molecular Probes) and sections were mounted with Prolong-Gold
antifade. Slides were analyzed on a FV1000 confocal microscope (Olympus, Tokyo,
Japan) equipped with 40 × and 60 × oil immersion objectives and the Olympus
Fluoview software.
Flow cytometry and sorting. Spheroid-dissociated cells were labeled with
primary antibodies (PE-conjugated anti-Lgr5, Alexa Fluor 488 conjugated anti-EphB2
or non-conjugated anti-CR1, described in the Antibodies and Reagents section) for
1 h on ice and, where necessary, with secondary antibodies for 30 min on ice, then
sorted with a FACSAria (BD Biosciences, San Jose, CA, USA) or analyzed with a
FACSCanto flow cytometer equipped with a DIVA software (BD Biosciences).
10 μg/ml 7-aminoactinomycin D (Sigma-Aldrich) was always added for dead cell
exclusion. The cell cycle status of colon CSC was assessed by staining dissociated
spheroids with 50 μg/ml propidium iodide dissolved in buffer 0.1% trisodium
citrate, 9.65 mM NaCl, 0.1% NP40, 200 μg/ml RNAse for 1 h at room temperature.
Analysis of debris/apoptotic cells was performed by gating the desired area of the
plot on the basis of physical parameters and subsequent fluorescence analysis on a
logarithmic scale.
Quantitative real-time PCR. Total RNA was extracted with TRIzol (Invitrogen)
following manufacturer’s instructions. 50 ng of RNA were reverse transcribed with M-MLV
reverse transcriptase (Invitrogen) and 200 ng of cDNA were used as template in the
PCR reactions. Specific primers (specified in Supplementary Table 3) were used for
Nanog, CR1, Nodal, Glypican, ALK4 and GRP78, while a TaqMan assay (Applied
Biosystems/Life Technologies, Carlsbad, CA, USA; Cat. 4351372) was used for Lgr5
amplification. Normalization was performed using β-actin as reference (TaqMan assay,
Applied Biosystems/Life Technologies, Cat. 4310881E) for Nanog, CR1 and Lgr5 and
GAPDH for Nodal, Glypican, ALK4 and GRP78. Values are expressed in terms of
2-ΔΔCT where ΔΔCT=ΔCTsample−ΔCTcalibrator. ΔCT is the difference in
threshold cycles between the specific RNA and β-actin amplicons, and CT is a
parameter given by StepOne Plus Real-Time PCR software by negative correlation with
an internal reference dye (ROX).
Western blotting. Cell lysates were obtained from approximately 2.5 × 105
spheroid cells by incubation of cell pellets in 1% NP40 lysis buffer (20 mM Tris HCl pH
7.2, 200 mM NaCl, 1% NP40) supplemented with protease inhibitor cocktail and
phosphatase inhibitor cocktails I and II (all from Sigma-Aldrich). Lysate concentrations
were determined by the Bradford assay (Bio-Rad Laboratories) and equal amounts of
proteins were loaded on a 12% precast gel (Invitrogen) and transferred to
nitrocellulose membranes. Blots were blocked with TBST 5% nonfat dry milk and
incubated overnight at 4 °C with primary antibodies (described in the Antibodies and
Reagents section), then incubated for 45 min with secondary HRP-conjugated
Figure 5 CR1 silencing inhibits CSC growth and self renewal in vitro and reduces Src–Akt activation. (a) CR1 mRNA level in spheroid line Pt1 mock transfected (Mock),
transfected with non-targeting small interfering RNA (CTRL siRNA) or with siRNA against CR1 (siRNA CR1), collected 24 h after transfection. *Po0.05 (b) Percentage of
colonies generated by spheroid cells treated as in a. Asterisks refer to the statistical significance of large and medium colonies compared between CTRL siRNA and siRNA CR1
samples. *Po0.05; ***Po0.001. Differences in the total number of colonies between the three samples are non-significant (c) CR1 mRNA expression in the colon cancer
spheroid line Pt1 and in the embryonic carcinoma cell line NTERA2 transduced with the pLKO vector containing either a non-targeting sequence (Non Target), the sh4889 or the
sh4890 CR1-silencing sequences. *Po0.05; ***Po0.001 (d) Colony formation by spheroid cells of line Pt1 transduced as in c. Asterisks flanking the histogram bars refer to the
statistical significance of colony size sections belonging to different samples. From left to right: Non Target versus sh4890, sh4890 versus sh4889 and Non Target versus sh4889.
*Po0.05; **Po0.01, ***Po0.001 (e) Growth (logarithmic scale) of spheroid line Pt1 transduced as in c, *Po0.05; **Po0.01 (f) Cell cycle analysis of CSC transduced with the
pLKO sh4890 CR1-silencing vector, 4 days after transduction. Right panels show the percentage of cells relative to each peak. Debri/apo refers to the percentage of events
including hypodiploid cells and debris, calculated as described in the Materials and Methods section (g) Immunoblot analysis of the indicated proteins in control CSC (Non Target)
and in CSC stably transduced with the pLKO sh4890 CR1-silencing vector (shCR1). PLK1, polo-like kinase 1; PARP, poly ADP ribose polymerase
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antibodies dissolved in TBST 1% BSA. Chemiluminescent signals were detected with
Super Signal West Pico (Pierce Pierce, Waltham, MA, USA). For subcellular
fractionation, the Q Proteome Cell Compartment Kit was used following the
manufacturer’s instructions (Qiagen, Germantown, MD, USA).
ELISA assay. 96-well plates were coated with 4 μg/ml of mouse anti-human
CR1 Ab (R&D Systems Inc., Cat. 842077) in PBS (137 mM NaCl; 2,7 mM KCl; 8,1
Na2HPO4; 1.5 mM KH2PO4 pH 7.5) overnight at 4 °C and then washed three times
with PBS-Tween20 0.05%. Aspecific binding sites were blocked with PBS-BSA 1%
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Figure 6 Cripto silencing inhibits tumor progression and decreases CSC numbers and tumor forming capacity in vivo. (a) mRNA levels, measured 48 h after infection, of
spheroid line Pt1 non-transduced (CTRL) or transduced with the inducible CR1 silencing lentiviral vector TRIPZ sh4890 in the absence or in the presence of doxycycline (Non-
induced and shCR1, respectively). **Po0.01. The difference between CTRL and Non-induced samples is non-significant (b) Cell numbers of Pt1 spheroid line treated as in a.
***Po0.001 (c) Size and normalized number of colonies formed in soft agar by spheroid line Pt1 treated as in a. *Po0.05; **Po0.01, ***Po0.001. Asterisks on the side of bars
refer to the statistical significance of colony size sections compared between Non-induced and shCR1 samples (d) In vivo growth of tumor xenografts obtained by subcutaneous
inoculation of Pt1 spheroids transduced with TRIPZ sh4890, non-induced (Non-induced) or in which CR1 silencing was induced by treating mice with doxycycline from day 0
(shCR1 induced from day 0) or at the time of tumor appearance (shCR1 induced from day 21). Results shown are the mean± S.D. of values obtained using six mice per group.
*Po0.05; **Po0.01, ***Po0.001 (e) Size and normalized number of colonies formed in soft agar by xenografts cells at the end of the experiment shown in d. *Po0.05;
**Po0.01, ***Po0.001. Asterisks on the side of bars refer to the statistical significance of colony size sections belonging to different samples. From left to right: Vector versus day
0, day 0 versus day 21, day 21 versus Vector. *Po0.05; **Po0.01, ***Po0.001 (f) Results of limiting dilution serial transplants performed with cells extracted from subcutaneous
xenografts expressing the TRIPZ sh4890 CR1-silencing sequence without doxycycline induction (Non-induced) or induced with doxycycline at the time of injection (shCR1)
shown in d. Cells were taken from dissociated xenografts at the end of the experiment, kept in the culture for one night in the presence or in the absence of doxycycline and
subcutaneously inoculated at the indicated numbers (100, 30 and 10 cells) in secondary recipients (four mice for each condition). Doxycycline was added to the drinking water of
secondary mice of the shCR1 group as described in Materials and Methods
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(300 μl/well) for at least 1 h at RT. After washing, the concentrated cell media (1 : 3
of starting volume) were added and incubated overnight at 4 °C. The plates were
incubated with 62.5 ng/ml of biotinylated anti-human CR1 Ab (R&D Systems Inc.,
Cat. 842079) in Reagent Diluent (1% BSA in PBS 1 × pH 7.5) for 2 h at RT. Finally,
the plates were incubated for 20 min at RTwith streptavidin complex conjugated with
horseradish peroxidase (R&D Systems Inc.). The signals were then visualized with
o-phenylenediamineperoxidase substrate (Sigma-Aldrich) and the relative absorbance
was read at 490 nm on a Benchmark microplate reader (Bio-Rad Laboratories).
Immunohistochemistry. Intestinal tissues were fixed in 4% PFA in PBS
overnight at 4 °C and were paraffin embedded. For immunohistochemistry, tissues
cut in 5-μm sections were deparaffinized in xylene and rehydrated in a series of
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Figure 7 CR1 is essential for CSC migration and growth at metastatic sites. (a) Flow cytometry analysis of CR1 and CD44v6 in colon CSC line Pt1 (b) Percentage of migrated
CSC in samples transduced with the TRIPZ sh4890 vector in the absence of doxycycline (Non-induced) or in the presence of doxycycline, which activates CR1 silencing mediated
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(Non-induced and shCR1, respectively), detected 4 months following caudal vein injection. Left: representative picture of mice 4 months after injection; right: quantification of lung
tumors derived from three different experiments. ***Po0.001 (d) Mice (eight) were inoculated in the spleen with CSCs transduced as above and left without doxycycline (Non-
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graded ethanol washes. Endogenous peroxidase activity was blocked with 3% H2O2
in methanol for 10 min. Antigen retrieval was performed by autoclaving slides in
citrate buffer (pH 6.0). CR1 protein was stained with anti-mouse-CR1 mAb (B3F6,
Biogen Idec, Weston, MA, USA) and the Vectastain ABC kit (Vector Laboratories
Inc, Burlingame, CA, USA) following the manufacturer’s instructions. Sections were
counterstained with hematoxylin.
Motility assay. 1 × 104 control or CR1-interfered CSCs were suspended in
200 μl of non-supplemented stem cell medium and plated into the upper wells of
matrigel-coated modified Boyden Chambers containing porous 8 mm diameter
polycarbonate membranes (Costar Scientific Corporation, Cambridge, MA, USA).
Lower wells contained 500 μl of stem cell medium supplemented with 20 ng/ml EGF
and 10 ng/ml basic FGF. After 4 days, the cells in the upper wells were removed,
whereas the cells that migrated to the lower wells were fixed, stained with DAPI in
PBS 1% NP40 for 5 min and counted under a fluorescence microscope. The
amount of migrated cells was quantified with the ImageJ program.
In vivo experiments. All animal experiments were conducted according to the
national Animal Experimentation guidelines (D.L.116/92) upon approval by the ISS
Animal Experimentation Committee. For tumorigenesis assays, female 6–8 weeks old
NSG mice were subcutaneously injected with 103 dissociated spheroid cells
resuspended in 100 μl Matrigel – CSC medium 1 : 1. Tumor volume was evaluated by
using an external digital caliper. For in vivo inducible CR1 silencing, doxycycline
200 μg/ml was kept in the drinking water throughout the experiment. For experiments
of CSC homing/metastasis, 104 dissociated spheroid cells were injected into the
caudal vein and tumor formation was monitored with an IVIS imaging system (Perkin
Elmer, Waltham, MA, USA). For serial transplantation experiments, cells derived from
dissociated xenografts were kept in culture overnight in the presence or in the
absence of doxycycline and inoculated subcutaneously. Doxycycline was provided to
mice throughout the experiment. Quantification of stem cell numbers was performed
with the ELDA method.25 For heterotopic spleen injection NSG mice were
anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg)
injected into the peritoneal cavity. 2 × 104 CSC transduced with TRIPZ sh4890 and
TWEEN-LUC-GFP were injected in the spleen during open laparotomy and mice were
monitored with IVIS. After primary tumor formation the spleen was removed and
doxycycline was added in the drinking water of the shCR1 group. Liver metastasis
growth was monitored with IVIS once a week for six weeks.
Statistical analysis. Data were analyzed using the R software with non-paired
double-tailed t test after verifying normal distribution of the population with Shapiro–
Wilk test. Results are presented as the mean±S.D. Statistical significance is
expressed as *P-value 0.01–0.05; **P-value 0.001–0.01 and ***P-value o0.001.
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